Extended Data Table 5.
Summary of 3BNC117 pharmakokinetics based on a 56-day period post infusion. (1) Estimation of half-lives; SD, standard deviation.
| Dose | HIV-1-status | Subjects | Method (subjects analyzed) | Cmax (μg/ml) | t1/2 (days) (1) | ||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||
| Mean | SD | Range | Mean | SD | Range | ||||
|
|
|
||||||||
| 1 mg | Neg. | 3 | ELISA (3) | 19.1 | 8.1 | 11.2 – 27.4 | n.d. | n.d. | n.d. |
| TZM.bl (3) | 26.2 | 2.4 | 23.5 – 27.8 | n.d. | n.d. | n.d. | |||
| 1 mg | Pos. | 3 | ELISA (3) | 24.1 | 9.1 | 15.7 – 33.8 | n.d. | n.d. | n.d. |
| TZM.bl (1) | 23.5 | n.d. | n.d. | n.d. | n.d. | n.d. | |||
| 3 mg | Neg. | 3 | ELISA (3) | 141.1 | 88.6 | 89.9 – 243.4 | 18.0 | 4.5 | 12.9 – 21.5 |
| TZM.bl (3) | 87.1 | 25.1 | 70.9 – 116.0 | 18.7 | 7.6 | 10.0 – 24.3 | |||
| 3 mg | Pos. | 3 | ELISA (3) | 73.7 | 35.7 | 32.6 – 97.6 | 9.2 | 0.4 | 8.7 – 9.6 |
| TZM.bl (3) | 50.6 | 15.7 | 32.6 – 61.7 | 11.2 | 2.2 | 9.5 – 13.73 | |||
| 10 mg | Neg. | 3 | ELISA (3) | 279.1 | 87.5 | 180.6 – 347.8 | 18.7 | 9.4 | 10.7 – 29.0 |
| TZM.bl (3) | 252.4 | 26.4 | 230.7 – 281.8 | 17.7 | 8.1 | 10.7 – 26.6 | |||
| 10 mg | Pos. | 3 | ELISA (3) | 235.4 | 80.0 | 178.2 – 326.8 | 8.1 | 2.4 | 6.6 – 10.9 |
| TZM.bl (3) | 213.6 | 52.6 | 174.4 – 273.4 | 8.8 | 4.3 | 6.5 – 13.7 | |||
| 30 mg | Neg. | 3 | ELISA (3) | 495.9 | 233.1 | 360.8 – 765.0 | 15.0 | 1.1 | 14.2 – 16.3 |
| TZM.bl (3) | 904.0 | 281.7 | 1166.3 – 606.2 | 16.4 | 1.3 | 15.2 –17.9 | |||
| 30 mg | Pos. | 6 | ELISA (6) | 669.8 | 199.7 | 410.2 – 976.4 | 9.9 | 3.3 | 5.8 – 13.7 |
| TZM.bl (3) | 840.1 | 118.4 | 717.4 – 953.7 | 8.9 | 2.3 | 6.7 – 11.2 | |||
| All | Neg. | 12 | ELISA (9) | – | – | – | 17.2 | 5.5 | 10.7 – 29.0 |
| TZM.bl (9) | – | – | – | 17.6 | 5.7 | 10.0 – 26.6 | |||
| All | Pos. | 15 | ELISA (12) | – | – | – | 9.3 | 2.6 | 5.7 – 13.7 |
| TZM.bl (9) | – | – | – | 9.6 | 2.9 | 6.1 – 13.7 | |||